Analysis of East Asia Subgroup in Study 309/KEYNOTE-775: Lenvatinib plus pembrolizumab versus treatment of physician’s choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer-Reference-Cited by-同舟云学术

Analysis of East Asia Subgroup in Study 309/KEYNOTE-775: Lenvatinib plus pembrolizumab versus treatment of physician’s choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer

Published:2024 Issue: Volume:35 Page:
ISSN:2005-0380
Container-title:Journal of Gynecologic Oncology
language:en
Short-container-title:J Gynecol Oncol

Author:

Yonemori Kan¹^ORCID,Fujiwara Keiichi²^ORCID,Hasegawa Kosei²^ORCID,Yunokawa Mayu³^ORCID,Ushijima Kimio⁴^ORCID,Suzuki Shiro⁵^ORCID,Shikama Ayumi⁶^ORCID,Minobe Shinichiro⁷^ORCID,Usami Tomoka⁸^ORCID,Kim Jae-Weon⁹^ORCID,Kim Byoung-Gie¹⁰^ORCID,Wang Peng-Hui¹¹^ORCID,Chang Ting-Chang¹²^ORCID,Yamamoto Keiko¹³^ORCID,Han Shirong¹⁴^ORCID,McKenzie Jodi¹⁵^ORCID,Orlowski Robert J.¹⁶^ORCID,Miura Takuma¹⁷^ORCID,Makker Vicky¹⁸^ORCID,Man Kim Yong¹⁹^ORCID

Affiliation:

1. Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.

2. Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan.

3. Department of Gynecology, Cancer Institute Hospital of JFCR, Tokyo, Japan.

4. Department of Obstetrics and Gynecology, Kurume University Hospital, Fukuoka, Japan.

5. Department of Gynecologic Oncology, Aichi Cancer Center Hospital, Aichi, Japan.

6. Department of Obstetrics and Gynecology, University of Tsukuba Hospital, Ibaraki, Japan.

7. Division of Gynecologic Oncology, Hokkaido Cancer Center, Hokkaido, Japan.

8. Department of Obstetrics and Gynecology, Ehime University Hospital, Ehime, Japan.

9. Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.

10. Division of Gynecologic Cancer, Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

11. Institute of Clinical Medicine, National Yang Ming Chiao Tung University; Department of Obstetrics and Gynecology, Taipei Veterans General Hospital; Female Cancer Foundation, Taipei, Taiwan; Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.

12. Department of Obstetrics and Gynecology, Linkou Chang Gung Memorial Hospital and Chang Gung University Medical College, Kueishan, Taoyuan City, Taiwan.

13. Oncology Science Unit, MSD K.K., Tokyo, Japan.

14. Biostatistics & Research Decision Sciences, MSD K.K., Tokyo, Japan.

15. Eisai Inc., Nutley, NJ, USA.

16. Global Clinical Development, Merck & Co., Inc., Rahway, NJ, USA.

17. Clinical Oncology, Eisai Co., Ltd., Tokyo, Japan.

18. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

19. Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan, Seoul, Korea.

Funder

Eisai Incorporated

Merck

Publisher

XMLink